Suppr超能文献

骨动蛋白与脉管系统:骨钙素、成纤维细胞生长因子-23和lipocalin-2的作用综述

Osteokines and the vasculature: a review of the effects of osteocalcin, fibroblast growth factor-23 and lipocalin-2.

作者信息

Millar Sophie A, Anderson Susan I, O'Sullivan Saoirse E

机构信息

Division of Graduate Entry Medicine and Medical Sciences, School of Medicine, Royal Derby Hospital, University of Nottingham, Derby, United Kingdom.

出版信息

PeerJ. 2019 Jul 24;7:e7139. doi: 10.7717/peerj.7139. eCollection 2019.

Abstract

Bone-derived factors that demonstrate extra-skeletal functions, also termed osteokines, are fast becoming a highly interesting and focused area of cross-disciplinary endocrine research. Osteocalcin (OCN), fibroblast growth factor-23 (FGF23) and lipocalin-2 (LCN-2), produced in bone, comprise an important endocrine system that is finely tuned with other organs to ensure homeostatic balance and health. This review aims to evaluate evidence of the direct involvement of these proteins in vascular cells and whether any causal roles in cardiovascular disease or inflammation can be supported. PubMed, Medline, Embase and Google Scholar were searched for relevant research articles investigating the exogenous addition of OCN, FGF23 or LCN-2 to vascular smooth muscle or endothelial cells. Overall, these osteokines are directly vasoactive across a range of human and animal vascular cells. Both OCN and FGF23 have anti-apoptotic properties and increase eNOS phosphorylation and nitric oxide production through Akt signalling in human endothelial cells. OCN improves intracellular insulin signalling and demonstrates protective effects against endoplasmic reticulum stress in murine and human endothelial cells. OCN may be involved in calcification but further research is warranted, while there is no evidence for a pro-calcific effect of FGF23 . FGF23 and LCN-2 increase proliferation in some cell types and increase and decrease reactive oxygen species generation, respectively. LCN-2 also has anti-apoptotic effects but may increase endoplasmic reticulum stress as well as have pro-inflammatory and pro-angiogenic properties in human vascular endothelial and smooth muscle cells. There is no strong evidence to support a pathological role of OCN or FGF23 in the vasculature based on these findings. In contrast, they may in fact support normal endothelial functioning, vascular homeostasis and vasodilation. No studies examined whether OCN or FGF23 may have a role in vascular inflammation. Limited studies with LCN-2 indicate a pro-inflammatory and possible pathological role in the vasculature but further mechanistic data is required. Overall, these osteokines pose intriguing functions which should be investigated comprehensively to assess their relevance to cardiovascular disease and health in humans.

摘要

具有骨骼外功能的骨源因子,也称为骨动蛋白,正迅速成为跨学科内分泌研究中一个非常有趣且备受关注的领域。骨钙素(OCN)、成纤维细胞生长因子23(FGF23)和脂质运载蛋白2(LCN-2)在骨中产生,构成一个重要的内分泌系统,该系统与其他器官精细调节,以确保体内平衡和健康。本综述旨在评估这些蛋白质直接参与血管细胞的证据,以及是否能支持其在心血管疾病或炎症中具有任何因果作用。在PubMed、Medline、Embase和谷歌学术上搜索了相关研究文章,这些文章研究了将OCN、FGF23或LCN-2外源添加到血管平滑肌或内皮细胞中的情况。总体而言,这些骨动蛋白对一系列人类和动物血管细胞具有直接的血管活性。OCN和FGF23都具有抗凋亡特性,并通过人内皮细胞中的Akt信号传导增加eNOS磷酸化和一氧化氮生成。OCN改善细胞内胰岛素信号传导,并对小鼠和人内皮细胞的内质网应激具有保护作用。OCN可能与钙化有关,但需要进一步研究,而没有证据表明FGF23具有促钙化作用。FGF23和LCN-2在某些细胞类型中增加增殖,并分别增加和减少活性氧的产生。LCN-2也具有抗凋亡作用,但可能会增加内质网应激,以及在人血管内皮和平滑肌细胞中具有促炎和促血管生成特性。基于这些发现,没有强有力的证据支持OCN或FGF23在脉管系统中具有病理作用。相反,它们实际上可能支持正常的内皮功能、血管稳态和血管舒张。没有研究考察OCN或FGF23是否可能在血管炎症中起作用。对LCN-2的有限研究表明其在脉管系统中具有促炎和可能的病理作用,但需要更多的机制数据。总体而言,这些骨动蛋白具有引人入胜的功能,应进行全面研究以评估它们与人类心血管疾病和健康的相关性。

相似文献

3
Role of osteokines in atherosclerosis.
Cell Biochem Funct. 2024 Aug;42(6):e4107. doi: 10.1002/cbf.4107.
5
Fibroblast growth factor 23 accelerates phosphate-induced vascular calcification in the absence of Klotho deficiency.
Kidney Int. 2014 May;85(5):1103-11. doi: 10.1038/ki.2013.332. Epub 2013 Oct 2.
6
Fibroblast growth factor 23 inhibits osteoblastic gene expression and induces osteoprotegerin in vascular smooth muscle cells.
Atherosclerosis. 2016 Oct;253:102-110. doi: 10.1016/j.atherosclerosis.2016.08.010. Epub 2016 Aug 20.
7
Metabolic Health and Disease: A Role of Osteokines?
Calcif Tissue Int. 2023 Jul;113(1):21-38. doi: 10.1007/s00223-023-01093-0. Epub 2023 May 17.
8
Klotho modulates FGF23-mediated NO synthesis and oxidative stress in human coronary artery endothelial cells.
Pflugers Arch. 2016 Sep;468(9):1621-35. doi: 10.1007/s00424-016-1858-x. Epub 2016 Jul 22.
9
Regulation of Energy Metabolism by Bone-Derived Hormones.
Cold Spring Harb Perspect Med. 2018 Jun 1;8(6):a031666. doi: 10.1101/cshperspect.a031666.
10
Osteocalcin expression in pulp inflammation.
J Endod. 2013 Jul;39(7):865-72. doi: 10.1016/j.joen.2012.12.035. Epub 2013 Feb 28.

引用本文的文献

1
Volatile organic compounds exposure associated with sarcopenia in US adults from NHANES 2011-2018.
Front Public Health. 2025 Jul 15;13:1613435. doi: 10.3389/fpubh.2025.1613435. eCollection 2025.
3
Research progress on resistance exercise therapy for improving cognitive function in patients with AD and muscle atrophy.
Front Aging Neurosci. 2025 Apr 8;17:1552905. doi: 10.3389/fnagi.2025.1552905. eCollection 2025.
4
Review of osteokines in spinal cord injury: potential biomarkers during rehabilitation.
J Orthop Surg Res. 2025 Jan 18;20(1):64. doi: 10.1186/s13018-024-05415-2.
5
Crosstalk between bone and brain in Alzheimer's disease: Mechanisms, applications, and perspectives.
Alzheimers Dement. 2024 Aug;20(8):5720-5739. doi: 10.1002/alz.13864. Epub 2024 Jun 2.
6
A view on the skin-bone axis: unraveling similarities and potential of crosstalk.
Front Med (Lausanne). 2024 Mar 4;11:1360483. doi: 10.3389/fmed.2024.1360483. eCollection 2024.
8
Serum neutrophil gelatinase-associated lipocalin as a potential biomarker for cognitive decline in spinal cord injury.
Front Neurol. 2023 Mar 6;14:1120446. doi: 10.3389/fneur.2023.1120446. eCollection 2023.
9
Bone-kidney axis: A potential therapeutic target for diabetic nephropathy.
Front Endocrinol (Lausanne). 2022 Oct 24;13:996776. doi: 10.3389/fendo.2022.996776. eCollection 2022.
10
Serum biomarkers for arterial calcification in humans: A systematic review.
Bone Rep. 2022 Jun 18;17:101599. doi: 10.1016/j.bonr.2022.101599. eCollection 2022 Dec.

本文引用的文献

2
FGF23 impairs peripheral microvascular function in renal failure.
Am J Physiol Heart Circ Physiol. 2018 Nov 1;315(5):H1414-H1424. doi: 10.1152/ajpheart.00272.2018. Epub 2018 Jul 20.
3
FGF23 in Cardiovascular Disease: Innocent Bystander or Active Mediator?
Front Endocrinol (Lausanne). 2018 Jun 27;9:351. doi: 10.3389/fendo.2018.00351. eCollection 2018.
4
Lipocalin-2 contributes to experimental atherosclerosis in a stage-dependent manner.
Atherosclerosis. 2018 Aug;275:214-224. doi: 10.1016/j.atherosclerosis.2018.06.015. Epub 2018 Jun 13.
6
FGF23 Actions on Target Tissues-With and Without Klotho.
Front Endocrinol (Lausanne). 2018 May 2;9:189. doi: 10.3389/fendo.2018.00189. eCollection 2018.
7
Fibroblast Growth Factor-23 and Risks of Cardiovascular and Noncardiovascular Diseases: A Meta-Analysis.
J Am Soc Nephrol. 2018 Jul;29(7):2015-2027. doi: 10.1681/ASN.2017121334. Epub 2018 May 15.
8
α-Klotho is a non-enzymatic molecular scaffold for FGF23 hormone signalling.
Nature. 2018 Jan 25;553(7689):461-466. doi: 10.1038/nature25451. Epub 2018 Jan 17.
9
Pleiotropic Actions of FGF23.
Toxicol Pathol. 2017 Oct;45(7):904-910. doi: 10.1177/0192623317737469. Epub 2017 Nov 2.
10
Osteocalcin, Vascular Calcification, and Atherosclerosis: A Systematic Review and Meta-analysis.
Front Endocrinol (Lausanne). 2017 Jul 31;8:183. doi: 10.3389/fendo.2017.00183. eCollection 2017.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验